Tesamorelin

Also known as: Egrifta, Egrifta WR

Evidence Tier Alow riskadvancedrx approved

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Prescription Only

This is an FDA-approved prescription product. It should only be obtained through licensed healthcare providers and pharmacies. Do not attempt to source through RUO or gray-market channels.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Overview

Tesamorelin is an FDA-approved GHRH analogue (brand name Egrifta/Egrifta WR) indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical endpoints commonly assessed at 26 weeks. Label warnings include increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance/diabetes, and hypersensitivity reactions. Contraindicated in active malignancy and pregnancy.

Research Details

Mechanism of Action

GHRH analogue that increases GH and IGF-1 levels.

Study Dose Range

FDA label: daily subcutaneous dosing (specific dose per formulation). Pivotal trials at 26 weeks.

Administration Routes

subcutaneous

Onset / Timeline

Clinical endpoints assessed at 26 weeks in pivotal studies.

Expected Effects

Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited.

Adverse Effects

Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity.

Contraindications

Active malignancy, pregnancy, pituitary gland disorders (per label).

Interaction Notes

CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected.

Related Goals

Fat Loss & MetabolismGH Axis Optimization

Known Interactions

caution with IGF-1 LR3

Tesamorelin increases IGF-1 (label); combining with IGF-axis agonists increases proliferative/hypoglycemia monitoring complexity.

caution with MK-677

Combining ibutamoren with tesamorelin increases GH-axis burden and glucose-management uncertainty.

Available From

Amino Club

consumer RUO · COA: product page COA viewer

10 mg / 20 mg (variant-dependent) · variant-dependent on product page

Consumer RUO; review product details carefully

Product page uses the vendor spelling 'Tesamorlin'. Deep-link mapping should stay tied to the canonical peptide ID tesamorelin.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Read this before you compare products

What Are Peptides?

A plain-language guide to what peptides are, how they are grouped, and why evidence quality matters before you research a compound.

Read guide

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Sermorelin

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

Tier B

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.